Telix Pharmaceuticals (TLX) Payables (2023 - 2025)

Telix Pharmaceuticals (TLX) has disclosed Payables for 3 consecutive years, with $163.5 million as the latest value for Q4 2025.

  • Quarterly Payables rose 57.29% to $163.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $163.5 million through Dec 2025, up 57.29% year-over-year, with the annual reading at $163.5 million for FY2025, 57.29% up from the prior year.
  • Payables for Q4 2025 was $163.5 million at Telix Pharmaceuticals, up from $103.9 million in the prior quarter.
  • The five-year high for Payables was $163.5 million in Q4 2025, with the low at $22.0 million in Q4 2023.
  • Average Payables over 3 years is $96.5 million, with a median of $103.9 million recorded in 2024.
  • The sharpest move saw Payables soared 372.3% in 2024, then skyrocketed 57.29% in 2025.
  • Over 3 years, Payables stood at $22.0 million in 2023, then skyrocketed by 372.3% to $103.9 million in 2024, then skyrocketed by 57.29% to $163.5 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $163.5 million, $103.9 million, and $22.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.